Dose–Volume Constraints for Thoracic, Abdominal, and Pelvic Carbon Ion Radiotherapy: A Literature Review

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-03-28 DOI:10.1002/cam4.70840

Maria Varnava, Mutsumi Tashiro, Masahiko Okamoto, Ken Ando, Nobutero Kubo, Hidemasa Kawamura, Masahiro Onishi, Kei Shibuya, Takuya Kumazawa, Takeru Ohtaka, Tatsuya Ohno

{"title":"Dose–Volume Constraints for Thoracic, Abdominal, and Pelvic Carbon Ion Radiotherapy: A Literature Review","authors":"Maria Varnava, Mutsumi Tashiro, Masahiko Okamoto, Ken Ando, Nobutero Kubo, Hidemasa Kawamura, Masahiro Onishi, Kei Shibuya, Takuya Kumazawa, Takeru Ohtaka, Tatsuya Ohno","doi":"10.1002/cam4.70840","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Applying dose–volume constraints is extremely important in ensuring the safe use of radiotherapy. However, constraints for carbon ion radiotherapy (CIRT) have not been established yet. This review aims to summarize dose–volume constraints for thoracic, abdominal, and pelvic CIRT that have been identified through previous research based on the Japanese models for relative biological effectiveness (RBE).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Constraints are reported for the lungs, liver, stomach, gastrointestinal tract, rectum, sigmoid, bladder, nerves, rib, femoral head, sacrum, and skin. The constraints are classified into hard and soft to aid in determining whether priority should be given to the target coverage or organ-at-risk (OAR) sparing during treatment planning.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Further research is necessary to verify the applicability of the reported constraints and to identify constraints for the OARs that have not been investigated yet.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 7","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70840","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70840","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Applying dose–volume constraints is extremely important in ensuring the safe use of radiotherapy. However, constraints for carbon ion radiotherapy (CIRT) have not been established yet. This review aims to summarize dose–volume constraints for thoracic, abdominal, and pelvic CIRT that have been identified through previous research based on the Japanese models for relative biological effectiveness (RBE).

Results

Constraints are reported for the lungs, liver, stomach, gastrointestinal tract, rectum, sigmoid, bladder, nerves, rib, femoral head, sacrum, and skin. The constraints are classified into hard and soft to aid in determining whether priority should be given to the target coverage or organ-at-risk (OAR) sparing during treatment planning.

Conclusions

Further research is necessary to verify the applicability of the reported constraints and to identify constraints for the OARs that have not been investigated yet.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胸、腹、盆腔碳离子放疗的剂量-体积限制：文献综述

背景应用剂量-体积限制对确保安全使用放射治疗极为重要。然而，碳离子放射治疗（CIRT）的约束条件尚未建立。本综述旨在根据日本的相对生物效应（RBE）模型，总结以往研究中确定的胸部、腹部和盆腔 CIRT 的剂量-体积限制。结果报告了肺、肝、胃、胃肠道、直肠、乙状结肠、膀胱、神经、肋骨、股骨头、骶骨和皮肤的限制因素。制约因素分为硬制约因素和软制约因素，以帮助确定在制定治疗计划时应优先考虑目标覆盖范围还是优先考虑风险器官（OAR）的切除。结论有必要开展进一步研究，以验证所报告的限制条件的适用性，并确定尚未研究的 OAR 限制条件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.